|
Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). |
|
|
Research Funding - Amgen; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Merck; Regeneron |
|
|
Honoraria - Amgen; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Pfizer; Replimune |
Consulting or Advisory Role - Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Merck Sharp & Dohme; Pfizer (Inst) |
Speakers' Bureau - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme |
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst) |
Travel, Accommodations, Expenses - Boehringer Ingelheim |
|
|
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Gilead Sciences; MSD; Novartis; Roche; Sandoz; Takeda |
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen; Merck; MSD; Novartis; Roche; Takeda |
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Merck (Inst); Novartis (Inst); Roche (Inst); Sandoz (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Celgene; Gilead Sciences; Janssen; MSD; Novartis; Roche |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Ipsen; Merck; Novartis; Pfizer; Roche/Genentech |
Consulting or Advisory Role - Ipsen; Merck; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Eisai; Merck Serono; MSD; Ono Pharmaceutical |
Consulting or Advisory Role - Amgen; Aspyrian Therapeutics; Bristol-Myers Squibb; Celgene; MSD; Ono Pharmaceutical; Pfizer |
Research Funding - Aspyrian Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst) |
|
|
Honoraria - Bristol-Myers Squibb; Merck Serono; MSD |
Consulting or Advisory Role - Bristol-Myers Squibb; MSD |
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; MSD |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; MSD |
|
|
Honoraria - Bayer; Bristol-Myers Squibb; Genesis Pharmaceuticals; Merck Serono; MSD Oncology; Roche |
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD Oncology; Pfizer |
Research Funding - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Demo Pharmaceutical; Kura Oncology; Pfizer; Pharmathen; Roche |
Travel, Accommodations, Expenses - Ipsen; MSD Oncology; Roche |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Nanobiotix |
|
|
Consulting or Advisory Role - AstraZeneca; Pfizer/EMD Serono |
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme |
Research Funding - Bristol-Myers Squibb; Merck Sharp & Dohme |
|
|
Honoraria - Bristol-Myers Squibb; Sanofi |
Consulting or Advisory Role - Merck Serono; Sanofi |
Research Funding - MSD (Inst) |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck KGaA; MSD; Pfizer; Roche |
Consulting or Advisory Role - Merck KGaA; MSD |
Research Funding - Merck KGaA (Inst); MSD (Inst) |
|
Brett Gordon Maxwell Hughes |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; MSD Oncology; Pfizer; Roche |
Research Funding - Amgen (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck KGaA; MSD; Nanobiotix; Roche |
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck KGaA; Roche |
|
|
Honoraria - Roche, Astra Zeneca, Eisai, Amgen, MSD, Novartis |
Consulting or Advisory Role - Roche, MSD, Amgen, Novartis, Boehringer Ingelheim, Taiho |
Speakers' Bureau - Roche, Astra Zeneca, Eisai, Amgen, MSD, Novartis |
Research Funding - MSD, Pfizer, Roche, Astra Zeneca (Inst) |
Travel, Accommodations, Expenses - Roche, MSD, Amgen, Novartis, Merck, Eisai, Taiho |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; MSD |
|
|
Honoraria - AstraZeneca; Eisai; Lilly; Pfizer |
Consulting or Advisory Role - Lilly; MSD; Roche |
Speakers' Bureau - Eisai; Lilly; Pfizer; Roche |
Research Funding - Amgen; MSD; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Eisai; Lilly; MSD; Pfizer |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
|
Stock and Other Ownership Interests - Merck |
Travel, Accommodations, Expenses - Merck; Merck |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
Consulting or Advisory Role - Aduro Biotech; Alligator Bioscience; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; CUE Biopharma; Debiopharm Group; Genentech/Roche; GlaxoSmithKline; MedImmune; Merck; VentiRx |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Debiopharm Group; Merck |